

### Vaccine Formulations

The present invention relates to the field of vaccines.

The immunogenic effect of traditional vaccines is  
5 mostly based on pathogens which have been killed or  
attenuated. In traditional vaccines the impurities in  
the vaccines themselves or other components of  
organisms act as adjuvants which potentiate and/or  
prolong the immunogenic activity of the actual antigen.  
10 For example, the diphtheria-tetanus-whooping cough  
vaccine contains two potent adjuvants originating from  
the whole-cell whooping cough vaccine (LPS =  
lipopolysaccharide and PT = pertussis toxin);  
Similarly, the whole cell typhus and cholera vaccines  
15 have potent adjuvants (LPS and cholera toxin); the BCG  
vaccine (Bacillus Calmette Guerin) has powerful non-  
specific immunostimulatory effects.

In contrast to the complex traditional vaccines, modern  
vaccines contain synthetic, recombinant or highly  
20 purified antigens in the form of proteins or peptides.  
These vaccines are regarded as safer but generally have  
the disadvantage of lower immunogenicity. To compensate  
for this disadvantage, adjuvants are added to the  
vaccines, to increase and prolong the specific immune  
25 response to antigens. Some adjuvants have the property  
of intensifying T-cell proliferation and the cellular  
immune response.

Most of the adjuvants used hitherto have side effects,  
however, and furthermore these adjuvants do not meet

the requirements imposed on the safety of adjuvants, such as stability with respect to adjuvant activity, minimal toxicity with no interaction with the antigen, and also degradability in the body and the absence of  
5 any immunogenic activity of their own.

A summary of current adjuvants which have hitherto been considered for use in vaccines is provided by Vogel; 1995, and by Gupta and Siber, 1995. They include:  
inorganic adjuvants in gel form (aluminium  
10 hydroxide/aluminium phosphate, calcium phosphate);  
bacterial adjuvants such as monophosphoryl lipid A and muramyl peptides, particulate adjuvants such as the so-called ISCOMS ("immunostimulatory complexes"),  
liposomes and biodegradable microspheres, adjuvants  
15 based on oil emulsions and emulsifiers such as Freund's adjuvant or IFA ("Incomplete Freund's adjuvant"),  
saponines (such as QS-21), squalene; synthetic adjuvants such as non-ionic block copolymers, muramyl peptide analogues, synthetic lipid A, synthetic  
20 polynucleotides and polycationic adjuvants such as polyarginine or polylysine (WO 97/30721).

The choice of an adjuvant is usually a compromise which is the result of balancing the toxicity and adjuvant effect of the substance in question.

25 In vaccine formulations, care has generally been taken up to now to achieve isotonicity; the common vaccine formulations are usually in a salt concentration which corresponds to about 150 mM of NaCl (about 300 mosmol/l). Common buffer formulations are PBS and  
30 HBS (phosphate-buffered or HEPES-buffered saline); e.g.

for an ISCOM vaccine PBS pH 7.4 was proposed (Barr and Mitchell, 1996).

The aim of the present invention was to provide a vaccine formulation which intensifies the activity of  
5 vaccines based on antigens in the form of peptides or proteins.

It was found that, surprisingly, the immunogenic activity of a peptide-based vaccine containing adjuvant is increased if the vaccine formulation has a low  
10 concentration of salt ions or is free from salts.

The invention thus relates to a vaccine containing one or more synthetic or highly purified natural peptides or proteins as antigen(s) as well as one or more adjuvants. The vaccine is characterised in that it  
15 takes the form of a solution or emulsion which is free from inorganic salt ions or has a low concentration of salt ions.

In the context of the vaccine according to the invention the phrase "low concentration of salt ions"  
20 denotes a concentration which is equal to or less than about 50% of the salt concentration of an isotonic solution, corresponding to about 75 mM saline solution.

For calculating the ion concentration it should be borne in mind that, when using peptide or protein  
25 antigens which themselves have a charge, this charge is not taken into account.

Preferably, the vaccine is substantially free from sodium, chloride and phosphate ions, and particularly preferably it is substantially free from all inorganic

salt ions ("substantially free" means that no salts have been added to the vaccine, but that there may be impurities present which have originated from reagents or there may be traces of ions; ions originating from  
5 adjuvants are not included in the calculation either, e.g. when using inorganic adjuvants).

In the event that the vaccine contains phosphate ions, e.g. originating from buffer solution, it is preferably free from sodium and chloride ions. If it contains  
10 sodium and/or chloride ions, it is preferably free from phosphate ions.

In one embodiment of the invention the vaccine contains antigen and adjuvant in salt-free medium, e.g. in distilled water.

- 15 In another preferred embodiment the vaccine according to the invention contains one or more water-soluble or water-emulsifiable substances which are capable of making the vaccine isotonic and increasing its immunogenic activity.
- 20 These substances are hereinafter designated "isotonic-making substances". Isotonic-making substances have the property of being able to generate physiological osmotic pressure by virtue of their molecular size and molecular structure.
- 25 Preferably, the isotonic-making substances are selected from among the group carbohydrates (sugars, sugar alcohols, oligosaccharides, polysaccharides), polyhydric alcohols, amino acids or lipids.

Preferably, the isotonic-making substance is a sugar, particularly a mono- or disaccharide such as maltose, fructose, galactose or saccharose, or a sugar alcohol such as sorbitol or mannitol.

- 5 The amino acids used may be isotonic, salt-free amino acid solutions such as are used e.g. in parenteral feeding. Solutions of this kind are commercially obtainable (e.g. from Leopold, Graz, Austria); if necessary they may be desalinated if they contain salt  
10 ions. Alternatively, isotonic, salt-free solutions which contain individual, preferably water-soluble, amino acids may be used.

- The lipids used may be, in particular, isotonic, salt-free fatty emulsions such as those used in parenteral  
15 feeding, for example. Emulsions of this kind are commercially obtainable (e.g. from Leopold, Graz, Austria); if necessary they may be desalinated if they contain salt ions. It is also possible to use long-chain hydrocarbons (e.g. paraffin oils), and also  
20 higher fatty acids such as linoleic acid, linolenic acid or palmitic acid, and fatty acid esters such as triglycerides.

- The isotonic-making substance is preferably present in a concentration such that the resulting solution is  
25 isotonic or slightly hypotonic, depending on the molecular weight.

Preferred sugar or sugar alcohol concentrations are within the range from about 200 - 400 mM, particularly in the range from 250 - 300 mM. The osmolarity of the

solution is conveniently between 200 - 400 mosmol/l, but the solution may also be strongly hypotonic.

Amino acid solutions should preferably have an osmolarity of between 200 - 400 mosmol/l, but may also  
5 be strongly hypotonic.

Lipid emulsions also preferably have an osmolarity of between 200 - 400 mosmol/l, but may also be strongly hypotonic.

In addition to the isotonic-making substance the  
10 solution comprising the vaccine according to the invention optionally contains a buffer substance. This might be, in particular, HEPES (N-[2-hydroxyethyl] piperazine-N'-[2-ethanesulphonic acid]), or TRIS (tris[hydroxymethyl]aminomethane). A buffer substance  
15 may be necessary to adjust the vaccine to a physiological pH if the primary solution is different from the physiological value.

The vaccine according to the invention is not subject to any restrictions regarding the peptide or protein  
20 antigens. The antigens may be naturally occurring immunogenic proteins, e.g. proteins from viral or bacterial pathogens or the fragments thereof or cellular breakdown products in the form of peptides; or tumour antigens or fragments thereof. In a preferred  
25 embodiment the antigen is a tumour antigen or a natural or synthetic peptide derived therefrom; in this case the vaccine is a tumour vaccine.

The quantity of effective antigen in the vaccine according to the invention may vary over a wide range.

The quantity of peptide depends, among other things, on the method of administration and the particular formulation used. The amount of peptide to be administered may be about 0.1 µg to about 10000 µg per  
5 vaccination dose, generally 1.0 µg to about 1000 µg, particularly about 10 µg to about 500 µg.

In a preferred embodiment of the invention the adjuvant is a substance such as that proposed in WO 97/30721, the disclosure of which is expressly referred to here,  
10 as an additive for protein or peptide vaccines, preferably a polycation such as polyarginine or polylysine which is optionally modified, e.g. with a sugar group.

The adjuvant used may also be, theoretically, any of  
15 the abovementioned adjuvants known for peptide- or protein-based vaccines. For example: inorganic adjuvants in gel form (aluminium hydroxide/aluminium phosphate, Warren et al., 1986; calcium phosphate, Relyvelt, 1986); bacterial adjuvants such as  
20 monophosphoryl lipid A (Ribi, 1984; Baker et al., 1988) and muramyl peptides (Ellouz et al., 1974; Allison and Byars, 1991; Waters et al., 1986); particulate adjuvants such as the so-called ISCOMS ("immunostimulatory complexes", Mowat and Donachie,  
25 1991; Takahashi et al., 1990; Thapar et al., 1991), liposomes (Mbawuike et al. 1990; Abraham, 1992; Phillips and Emili, 1992; Gregoriadis, 1990) and biodegradable microspheres (Marx et al., 1993);  
adjuvants based on oil emulsions and emulsifiers such  
30 as Freund's adjuvant or IFA ("Incomplete Freund's adjuvant" (Stuart-Harris, 1969; Warren et al., 1986),

SAF (Allison and Byars, 1991), saponines (such as QS-21; Newman et al., 1992), squalene/squalane (Allison and Byars, 1991); synthetic adjuvants such as non-ionic block copolymers (Hunter et al., 1991), muramyl peptide analogues (Azuma, 1992), synthetic lipid A (Warren et al., 1986; Azuma, 1992), synthetic polynucleotides (Harrington et al., 1978) and polycationic adjuvants (WO 97/30721).

The skilled person will be able to define suitable antigen/adjuvant formulations from the specialist literature mentioned hereinbefore and, working from this starting point, find an isotonic-making substance which is capable of increasing the efficacy of the formulation or, while retaining the same efficacy, reducing the proportion of adjuvant in the formulation, which offers a critical advantage in the case of adjuvants with side effects.

It has surprisingly been found, within the scope of the present invention, that a salt-free tumour vaccine made isotonic with sorbitol, containing an MHC-binding peptide derived from a tumour antigen as well as polyarginine as adjuvant, has a more potent antitumour activity than a conventionally formulated tumour vaccine, i.e. containing an isotonic salt concentration, which is identical in terms of the peptide/adjuvant. It was found that the peptides together with the adjuvant dissolve better in sorbitol solution than in conventional PBS buffer. Without wishing to be tied to the theory, the improved activity of the vaccine, apart from the improved solubility, would appear to be due to the fact that the interaction



between the peptide and adjuvant is made easier and thus the activity of the adjuvant is intensified. The improved activity of the vaccine may possibly also be due to a co-adjuvant activity of the isotonic-making  
5 substance, e.g. sorbitol, i.e. this substance (sorbitol) as such has a certain adjuvant effect which increases the activity of the primary adjuvant.

The following method is appropriately used to achieve the ideal vaccine formulation: starting from a defined  
10 antigen, which is intended to provoke the desired immune response, in a first step an adjuvant matched to the antigen is found, as described in the specialist literature, particularly in WO 97/30721. In a next step the vaccine is optimised by adding various isotonic-  
15 making substances as defined in the present inventions, preferably sugars and/or sugar alcohols, in an isotonic or slightly hypotonic concentration, to the mixture of antigen and adjuvant, with the composition otherwise being identical, and adjusting the solution to a  
20 physiological pH in the range from pH 4.0 to 10.0, particularly 7.4. Then, in a first step as described in the example of the present application, the substances or the concentration thereof which will improve the solubility of the antigen/adjuvant composition compared  
25 with a conventional, saline-buffered solution are determined. The improvement in the solubility characteristics by a candidate substance is a first indication that this substance is capable of bringing about an increase in the immunogenic activity of the  
30 vaccine.

Since one of the possible prerequisites for an increase in the cellular immune response is increased binding of the antigen to APCs (antigen presenting cells), in a next step an investigation can be made to see whether  
5 the substance leads to an increase of this kind. The procedure used may be analogous to that described in the definition of the adjuvant, e.g. incubating APCs with fluorescence-labelled peptide or protein, adjuvant and isotonic-making substance. An increased uptake or  
10 binding of the peptide to APCs brought about by the substance can be determined by comparison with cells which have been mixed with peptide and adjuvant alone or with a peptide/adjuvant composition which is present in conventional saline buffer solution, using  
15 throughflow cytometry.

In a second step the candidate substances may be investigated *in vitro* to see whether and to what extent their presence is able to increase the presentation of a peptide to APCs; the MHC concentration on the cells  
20 may be measured using the methods described in WO 97/30721 for testing peptides.

Another possible way of testing the efficiency of a formulation is by using an *in vitro* model system. In this, APCs are incubated together with adjuvant,  
25 peptide and candidate substance and the relative activation of a T-cell clone which specifically recognises the peptide used is measured (Coligan et al., 1991; Lopez et al., 1993).

The efficiency of the formulation may optionally also  
30 be demonstrated by the cellular immune response by

detecting a "delayed-type hypersensitivity" (DTH) reaction in immunised animals.

Finally, the immunomodulatory activity of the formulation is measured in animal tests. In the case of a tumour vaccine as in the present example, established tumour models having known peptide sequences recognised by immune cells may be used, *inter alia*. The vaccine, containing different buffer substances but having a constant peptide/adjuvant composition, is administered to the test animals. The protection from tumour growth is a measurement of the efficacy of a tumour vaccine.

#### Example

The experiments were carried out as described in WO 97/30721.

- a
- 15 a) DBA/2 mice were inoculated three times at intervals of one week with a mixture of 100 µg of MHC Class I binding peptide SYFPETHI<sub>1</sub> (SEQ ID NO: 1) (known as "P815 JAK1") and 75 µg of polyarginine (degree of polymerisation 70, SIGMA Chemicals, St. Louis MO) per animal. The
  - 20 peptide/adjuvant solution was administered in sorbitol solution (270 mM sorbitol, 5 mM HEPES) or phosphate-buffered saline solution (PBS, GIBCO BRL). Control mice were either given 100 µg of peptide/animal with no adjuvant in sorbitol buffer or were not vaccinated. A
  - 25 week after the last vaccination, 10<sup>4</sup> viable tumour cells were injected and tumour growth was measured weekly.

The results of the tests are shown in Fig. 1. The Figure shows a comparison of the efficiency of the P815 JAK1 vaccine in sorbitol solution as against a

vaccine in buffered isotonic saline solution in the animal model. It was found that animals that had been given the vaccine in sorbitol solution were better protected than mice that had been inoculated with peptide/polyarginine in PBS.

a) b) For the solubility tests, mixtures of fluorescence-labelled peptide LFEAIEGFI, or GYKDGNEYI, were prepared: (SEQ ID NO: 2) (SEQ ID NO: 2)  
 100 µg of fluorescence-labelled peptide were combined with 75 µg of polyarginine (Arg; degree of polymerisation 70, SIGMA Chemicals, St. Louis MO) either in sorbitol solution or HEPES-buffered saline solution (HBS: 20 mM HEPES pH 7.5, 150 mM NaCl). After three hours the amount of dissolved fluorescence was measured by determining the extinction at 490 nm. The test protein used was Green Fluorescent protein.

Fig. 2 and Fig. 3 show a comparison of the solubility of the complexes after mixing in buffered saline solution or sorbitol solution. The two fluorescence-labelled peptides (Fig. 2A and Fig. 2B) and the Green Fluorescent protein (GFP; about 30 Kd; Fig. 3) were included in this experiment. Adding the vaccine in sorbitol solution resulted in a significantly better solubility and recovery (increased fluorescence) both with the two tested peptides and with GFP.

## Literature

- Abraham, E., 1992, Vaccine 10, 461-468
- 5 Allison, A.C., and Byars, N.E., 1991, Mol Immunol 28,  
279-284
- Azuma, I., 1992, Vaccine 10, 1000-1004
- Baker, P.J., et al., 1988, Infect Immun 56, 3064-3066
- Coligan, J.E. et al., 1991, Current Protocols in  
10 Immunology, Wiley, New York
- Ellouz, F., et al., 1974, Biochem Biophys Res Commun  
59, 1317-1325
- Gupta, R.K. and Siber G.R., 1995, Vaccine 13, 1263-1276
- Gregoriadis, G., 1990, Immunol Today 11, 89-97
- 15 Harrington, D.G., et al., 1978, Infect Immun 24,  
160-166
- Hunter, R., et al., 1991, Vaccine 9, 250-255
- Lopez, J.A., et al., 1993, Eur. J. Immunol. 23, 217-223
- Marx, P.A., et al., 1993, Science 28, 1323-1327
- 20 Mbawuike, I.N., et al., 1990, Vaccine 8, 347-352
- Mowat, A.M., and Donachie, A.M., 1991, Immunol Today  
12, 383-385

Newman, M.J., et al., 1992, J Immunol 148, 2357-2362

Phillips, N.C. and Emili, A, 1992, Vaccine 10, 151-158

Rammensee, H.G., et al., 1995, Immunogenetics 41,  
178-228

- 5 Relyvelt, E.H., 1986, Develop Biol Standard, 65,  
131-136

Ribi, E., 1984, J Biol Res Mod, 3, 1-9

Stuart-Harris, C.H., 1969, Bull WHO 41, 617-621

Takahashi, H., et al., 1990, Nature 344, 873-875

- 10 Thapar, M.A., et al., 1991, Vaccine 9, 129-133

Vogel, F. R. 1995, Ann N Y Acad Sci 754, 153-160

Warren, H.S., et al., 1986, Ann Rev Immunol 4, 369-388

Waters, R.V., et al., 1986, Infect Immun 52, 816-825